<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03623334</url>
  </required_header>
  <id_info>
    <org_study_id>STU 072010-050</org_study_id>
    <nct_id>NCT03623334</nct_id>
  </id_info>
  <brief_title>Phase I Study of Accelerated Hypofractionated Image-Guided Radiation Therapy</brief_title>
  <official_title>Phase I Study of Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-IV Non-Small Cell Lung Cancer and Poor Performance Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to determine whether daily image guidance and motion assessment/control&#xD;
      will allow treatment of poor performance status patients with stage II-IV NSCLC, who would&#xD;
      benefit from local therapy, with an accelerated course of hypofractionated radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects for this study will be enrolled by the Moncrief Radiation oncology Department at the&#xD;
      Simmons Cancer Center.&#xD;
&#xD;
      Primary objective: To escalate the dose of accelerated, hypofractionated, image-guided&#xD;
      conformal radiotherapy to a potent tumorcidal dose without exceeding the maximum tolerated&#xD;
      dose in treatment of stage ii-iV nSCLC in patients with poor performance status.&#xD;
&#xD;
      Secondary objectives: To evaluate local regional tumor control and overall survival in&#xD;
      patients with stage ii-iV nSCLC and poor performance status treated with accelerated,&#xD;
      hypofractionated, image-guided conformal radiotherapy.&#xD;
&#xD;
      Schema&#xD;
&#xD;
      number of patients between 7-45 (depending on tolerance)&#xD;
&#xD;
      Patients in each dose cohort will all be treated as a single group for dose escalation. The&#xD;
      starting dose will be 3.33 Gy per fraction for 15 fractions (total dose 50 Gy). Subsequent&#xD;
      cohorts of patients will receive a higher dose per fraction as follows:&#xD;
&#xD;
      Cohort No. Fractions Dose per fraction (Gy) Total Dose (Gy) No. Patients&#xD;
&#xD;
        1. 15 3.33 50 7-15&#xD;
&#xD;
        2. 15 3.67 55 7-15&#xD;
&#xD;
        3. 15 4.00 60 7-15&#xD;
&#xD;
      Minimum waiting periods will be assigned between each dose cohort to observe toxicity.&#xD;
&#xD;
      Screening Procedures&#xD;
&#xD;
      each study participant will have the following exams, tests or procedure to help determine if&#xD;
      they are qualified to be in this study:&#xD;
&#xD;
      Within 8 weeks of enrollment :&#xD;
&#xD;
        -  Computed tomographic (CT) with contrast of the lung and upper abdomen. a CT done in&#xD;
           conjunction with a Positron emission Tomography (PeT) scan is satisfactory as long as&#xD;
           the images are of adequate quality to be interpreted by a radiologist.&#xD;
&#xD;
        -  an MRi of the brain with contrast (or CT if MRi is medically contraindicated).&#xD;
&#xD;
        -  Complete Blood Count (CBC) with differential&#xD;
&#xD;
        -  Charleston Comorbidity index completion&#xD;
&#xD;
      Within 3 days prior to radiotherapy: urine or serum pregnancy test in females of&#xD;
      child-bearing capacity.&#xD;
&#xD;
      Within 12 weeks of enrollment:&#xD;
&#xD;
      * Pulmonary function tests including spirometry for forced expiratory volume in 1 second&#xD;
      (FeV-1), diffusing capacity (DLCo), and arterial blood gas (Pao-2).&#xD;
&#xD;
      Prior to enrollment on the study: Tissue biopsy or cytology confirming non-small cell lung&#xD;
      cancer.&#xD;
&#xD;
      Treatment Protocol treatment must begin within 4 weeks after patient registration to the&#xD;
      trial. Patients will receive 15 fractions of radiation. Total dose will depend on the dose&#xD;
      cohort of the study (see schema). The starting dose level will be 3.33 Gy per fraction for 15&#xD;
      fractions (total dose [?] 50 Gy).&#xD;
&#xD;
      Patients must not receive other concomitant antineoplastic therapy (including standard&#xD;
      fractionated radiotherapy to the chest, chemotherapy, biological therapy, vaccine therapy,&#xD;
      and surgery) within a week prior to, during, or within one week after completing&#xD;
      hypofractionated image-guided radiation therapy on protocol.&#xD;
&#xD;
      Follow-up Patients will be followed until death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2009</start_date>
  <completion_date type="Actual">February 10, 2018</completion_date>
  <primary_completion_date type="Actual">November 2, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicity</measure>
    <time_frame>90 days after start of treatment up to 1 year</time_frame>
    <description>A dose limiting toxicity (DLT) is defined as treatment-related (definitely and probably, but not possibly related to treatment*) grade 3 adverse events (per CTCAE, v.3.0, with the exception of pulmonary function tests)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Regional Tumor Control at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Regional Tumor Control at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Regional Tumor Control at 9 Months</measure>
    <time_frame>9 months</time_frame>
    <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Regional Tumor Control at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Regional Tumor Control at 16 Months</measure>
    <time_frame>16 months</time_frame>
    <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Regional Tumor Control at 20 Months</measure>
    <time_frame>20 months</time_frame>
    <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Overall survival is defined as participants alive during the research period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level A: IGRT 3.33Gy x 15 Fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Image-guided radiation therapy (IGRT) dose of 3.33Gy for 15 fractions (total dose = 50 Gy) which is given over the course of about 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level B: IGRT 3.67Gy x 15 Fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 55 Gy) which is given over the course of about 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level C: IGRT 4.00Gy x 15 Fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 60 Gy) which is given over the course of about 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Image-Guided Radiation Therapy</intervention_name>
    <description>Radiotherapy to a potent tumorcidal dose</description>
    <arm_group_label>Dose Level A: IGRT 3.33Gy x 15 Fractions</arm_group_label>
    <arm_group_label>Dose Level B: IGRT 3.67Gy x 15 Fractions</arm_group_label>
    <arm_group_label>Dose Level C: IGRT 4.00Gy x 15 Fractions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients must be willing and capable to provide informed consent to participate in&#xD;
             the protocol.&#xD;
&#xD;
          2. Patients must have appropriate staging studies identifying them as AJCC stage II, III&#xD;
             or IV non small cell lung cancer, [according to AJCC Staging, 6th edition; see&#xD;
             appendix III], or recurrent non small cell lung cancer. Histologic confirmation of&#xD;
             cancer will be required by biopsy or cytology.&#xD;
&#xD;
          3. Patients must have the potential for benefit from local therapy (at the discretion of&#xD;
             the investigator).&#xD;
&#xD;
          4. Patient must have a Zubrod performance status of 2 or greater Or Patient must have had&#xD;
             &gt;10% weight loss in the past 6 months Or Patient is not eligible for concurrent&#xD;
             chemoradiation as determined by a Medical Oncologist and Radiation Oncologist&#xD;
&#xD;
          5. Age â‰¥ 18.&#xD;
&#xD;
          6. The tumor must be ineligible for definitive surgical resection.&#xD;
&#xD;
          7. The tumor must be ineligible for stereotactic body radiation therapy.&#xD;
&#xD;
          8. Patients must have measurable or evaluable disease.&#xD;
&#xD;
          9. Women of childbearing potential and male participants must agree to use an effective&#xD;
             method of contraception.&#xD;
&#xD;
         10. Patients must sign study specific informed consent prior to study entry.&#xD;
&#xD;
         11. Patients must complete all required pretreatment evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of small cell histology.&#xD;
&#xD;
          2. Tumor eligible for definitive surgical resection.&#xD;
&#xD;
          3. Tumor eligible for definitive stereotactic body radiation therapy.&#xD;
&#xD;
          4. Prior radiotherapy to the region of the study cancer that would result in overlap of&#xD;
             radiation therapy fields.&#xD;
&#xD;
          5. Chemotherapy given within one week of study registration.&#xD;
&#xD;
          6. Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo&#xD;
             or fetus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Timmerman</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <results_first_submitted>October 10, 2019</results_first_submitted>
  <results_first_submitted_qc>April 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2021</results_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Robert Timmerman</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03623334/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (Total 50 Gy)</title>
          <description>Image-guided radiation therapy (IGRT) dose which is given over the course of about 3 weeks&#xD;
Patients with stage II to IV or recurrent NSCLC and Eastern Cooperative Oncology Group performance status of 2 or greater and not candidates for surgical resection, stereotactic radiation, or concurrent chemoradiation were eligible. Highly conformal radiation therapy was given to treat intrathoracic disease in 15 fractions to a total of 50, 55, or 60 Gy.</description>
        </group>
        <group group_id="P2">
          <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (Total 55-Gy )</title>
          <description>Image-guided radiation therapy (IGRT) which is given over the course of about 3 weeks&#xD;
Patients with stage II to IV or recurrent NSCLC and Eastern Cooperative Oncology Group performance status of 2 or greater and not candidates for surgical resection, stereotactic radiation, or concurrent chemoradiation were eligible. Highly conformal radiation therapy was given to treat intrathoracic disease in 15 fractions to a total of 50, 55, or 60 Gy.</description>
        </group>
        <group group_id="P3">
          <title>Dose Level C: IGRT 4Gy x 15 Fractions ( Total 60Gy)</title>
          <description>4 Gy per fraction for a total dose of 60 Gy will be tested. Image-guided radiation therapy (IGRT) dose which is given over the course of about 3 weeks&#xD;
Patients with stage II to IV or recurrent NSCLC and Eastern Cooperative Oncology Group performance status of 2 or greater and not candidates for surgical resection, stereotactic radiation, or concurrent chemoradiation were eligible. Highly conformal radiation therapy was given to treat intrathoracic disease in 15 fractions to a total of 50, 55, or 60 Gy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (Total 50Gy)</title>
          <description>Image-guided radiation therapy (IGRT) does of 3.33Gy for 15 fractions (total dose = 50 Gy) which is given over the course of about 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (Total 55Gy)</title>
          <description>Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 55 Gy) which is given over the course of about 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Dose Level C: IGRT 4Gy x 15 Fractions ( Total 60Gy)</title>
          <description>4 Gy per fraction for a total dose of 60 Gy will be tested. Image-guided radiation therapy (IGRT) dose which is given over the course of about 3 weeks&#xD;
Patients with stage II to IV or recurrent NSCLC and Eastern Cooperative Oncology Group performance status of 2 or greater and not candidates for surgical resection, stereotactic radiation, or concurrent chemoradiation were eligible. Highly conformal radiation therapy was given to treat intrathoracic disease in 15 fractions to a total of 50, 55, or 60 Gy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="30" upper_limit="84"/>
                    <measurement group_id="B2" value="65" lower_limit="30" upper_limit="84"/>
                    <measurement group_id="B3" value="65" lower_limit="30" upper_limit="84"/>
                    <measurement group_id="B4" value="65" lower_limit="30" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicity</title>
        <description>A dose limiting toxicity (DLT) is defined as treatment-related (definitely and probably, but not possibly related to treatment*) grade 3 adverse events (per CTCAE, v.3.0, with the exception of pulmonary function tests)</description>
        <time_frame>90 days after start of treatment up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (50 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.33 Gy per fraction for 15 fractions (total dose = 50 Gy).</description>
          </group>
          <group group_id="O2">
            <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (55 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.67 Gy per fraction for 15 fractions (total dose = 55 Gy).</description>
          </group>
          <group group_id="O3">
            <title>Dose Level C: IGRT 4.00Gy x 15 Fractions (60 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 4.00 Gy per fraction for 15 fractions (total dose = 60 Gy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicity</title>
          <description>A dose limiting toxicity (DLT) is defined as treatment-related (definitely and probably, but not possibly related to treatment*) grade 3 adverse events (per CTCAE, v.3.0, with the exception of pulmonary function tests)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Regional Tumor Control at 3 Months</title>
        <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
        <time_frame>3 months</time_frame>
        <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (50 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.33 Gy per fraction for 15 fractions (total dose = 50 Gy).</description>
          </group>
          <group group_id="O2">
            <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (55 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.67 Gy per fraction for 15 fractions (total dose = 55 Gy).</description>
          </group>
          <group group_id="O3">
            <title>Dose Level C: IGRT 4.00Gy x 15 Fractions (60 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 4.00 Gy per fraction for 15 fractions (total dose = 60 Gy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Regional Tumor Control at 3 Months</title>
          <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
          <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Regional Tumor Control at 6 Months</title>
        <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
        <time_frame>6 months</time_frame>
        <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (50 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.33 Gy per fraction for 15 fractions (total dose = 50 Gy).</description>
          </group>
          <group group_id="O2">
            <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (55 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.67 Gy per fraction for 15 fractions (total dose = 55 Gy).</description>
          </group>
          <group group_id="O3">
            <title>Dose Level C: IGRT 4.00Gy x 15 Fractions (60 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 4.00 Gy per fraction for 15 fractions (total dose = 60 Gy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Regional Tumor Control at 6 Months</title>
          <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
          <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Regional Tumor Control at 9 Months</title>
        <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
        <time_frame>9 months</time_frame>
        <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (50 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.33 Gy per fraction for 15 fractions (total dose = 50 Gy).</description>
          </group>
          <group group_id="O2">
            <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (55 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.67 Gy per fraction for 15 fractions (total dose = 55 Gy).</description>
          </group>
          <group group_id="O3">
            <title>Dose Level C: IGRT 4.00Gy x 15 Fractions (60 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 4.00 Gy per fraction for 15 fractions (total dose = 60 Gy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Regional Tumor Control at 9 Months</title>
          <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
          <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Regional Tumor Control at 12 Months</title>
        <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
        <time_frame>12 months</time_frame>
        <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (50 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.33 Gy per fraction for 15 fractions (total dose = 50 Gy).</description>
          </group>
          <group group_id="O2">
            <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (55 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.67 Gy per fraction for 15 fractions (total dose = 55 Gy).</description>
          </group>
          <group group_id="O3">
            <title>Dose Level C: IGRT 4.00Gy x 15 Fractions (60 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 4.00 Gy per fraction for 15 fractions (total dose = 60 Gy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Regional Tumor Control at 12 Months</title>
          <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
          <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Regional Tumor Control at 16 Months</title>
        <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
        <time_frame>16 months</time_frame>
        <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (50 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.33 Gy per fraction for 15 fractions (total dose = 50 Gy).</description>
          </group>
          <group group_id="O2">
            <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (55 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.67 Gy per fraction for 15 fractions (total dose = 55 Gy).</description>
          </group>
          <group group_id="O3">
            <title>Dose Level C: IGRT 4.00Gy x 15 Fractions (60 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 4.00 Gy per fraction for 15 fractions (total dose = 60 Gy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Regional Tumor Control at 16 Months</title>
          <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
          <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Regional Tumor Control at 20 Months</title>
        <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
        <time_frame>20 months</time_frame>
        <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (50 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.33 Gy per fraction for 15 fractions (total dose = 50 Gy).</description>
          </group>
          <group group_id="O2">
            <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (55 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.67 Gy per fraction for 15 fractions (total dose = 55 Gy).</description>
          </group>
          <group group_id="O3">
            <title>Dose Level C: IGRT 4.00Gy x 15 Fractions (60 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 4.00 Gy per fraction for 15 fractions (total dose = 60 Gy).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Regional Tumor Control at 20 Months</title>
          <description>Local control is defined as the absence of isolated progression (stable disease or responsive disease at last follow-up) within the primary tumor. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions.</description>
          <population>Only convenient sample were included. Those who died, lost to follow-up, refused scans were not included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at 6 Months</title>
        <description>Overall survival is defined as participants alive during the research period.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (50 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.33 Gy per fraction for 15 fractions (total dose = 50 Gy).</description>
          </group>
          <group group_id="O2">
            <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (55 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 3.67 Gy per fraction for 15 fractions (total dose = 55 Gy).</description>
          </group>
          <group group_id="O3">
            <title>Dose Level C: IGRT 4.00Gy x 15 Fractions (60 Gy)</title>
            <description>In this cohort, the starting dose of Image-Guided Radiation Therapy (IGRT) will be 4.00 Gy per fraction for 15 fractions (total dose = 60 Gy).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 6 Months</title>
          <description>Overall survival is defined as participants alive during the research period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This was collected over a period of 12 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dose Level A: IGRT 3.33Gy x 15 Fractions (50 Gy)</title>
        </group>
        <group group_id="E2">
          <title>Dose Level B: IGRT 3.67Gy x 15 Fractions (55 Gy)</title>
        </group>
        <group group_id="E3">
          <title>Dose Level C: IGRT 4.00Gy x 15 Fractions (60 Gy</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>G2 or higher dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>G2 or higher Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>â‰¤G2 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>â‰¤G2 Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Pulmonary/ Upper Respiratory Infection:&#xD;
Lung (Pnemonia)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Planned statistical analysis was not able to be performed due to the poor overall survival of the study population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sarah Hardee</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-1836</phone>
      <email>sarah.hardee@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

